PuSH - Publication Server of Helmholtz Zentrum München: Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Marazioti, A.* ; Lilis, I.* ; Vreka, M. ; Apostolopoulou, H.* ; Kalogeropoulou, A.* ; Giopanou, I.* ; Giotopoulou, G.A.* ; Krontira, A.C.* ; Iliopoulou, M.* ; Kanellakis, N.I.* ; Agalioti, T.* ; Giannou, A.D.* ; Jones-Paris, C.* ; Iwakura, Y.* ; Kardamakis, D.* ; Blackwell, T.S.* ; Taraviras, S.* ; Spella, M.* ; Stathopoulos, G.T.

Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion.

Nat. Commun. 9:672 (2018)

Publ. Version/Full Text

Research data

DOI

	Open Access Gold

Abstract
Metrics
Extra information

Malignant pleural effusion (MPE) is a frequent metastatic manifestation of human cancers. While we previously identified KRAS mutations as molecular culprits of MPE formation, the underlying mechanism remained unknown. Here, we determine that non-canonical IKK alpha-RelB pathway activation of KRAS-mutant tumor cells mediates MPE development and this is fueled by host-provided interleukin IL-1 beta. Indeed, IKK alpha is required for the MPE-competence of KRAS-mutant tumor cells by activating non-canonical NF-kappa B signaling. IL-1 beta fuels addiction of mutant KRAS to IKK alpha resulting in increased CXCL1 secretion that fosters MPE-associated inflammation. Importantly, IL-1 beta-mediated NF-kappa B induction in KRAS-mutant tumor cells, as well as their resulting MPE-competence, can only be blocked by co-inhibition of both KRAS and IKK alpha, a strategy that overcomes drug resistance to individual treatments. Hence we show that mutant KRAS facilitates IKK alpha-mediated responsiveness of tumor cells to host IL-1 beta, thereby establishing a host-to-tumor signaling circuit that culminates in inflammatory MPE development and drug resistance.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

12.353

2.912